Evaluation of New Indomethacin Dosage Forms
Author:
- 12 November 1983
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 3 (6) , 324-331
Abstract
Indomethacin, an indole derivative nonsteroidal anti‐inflammatory drug, has been available since the early 1960s in gelatin capsules. In 1982, a sustained release product, Indocin® SR, was marketed. Awaiting marketing approval is a unique controlled release form of indomethacin, Indos.® The disposition of indomethacin includes enterohepatic cycling and extensive metabolism to inactive metabolites. Enterohepatic cycling makes interpretation of bioavailability estimates of indomethacin dosage forms difficult. The relationship of indomethacin plasma concentrations to therapeutic effects and side effects is inconclusive. It appears in vivo prostaglandin inhibition occurs at very low plasma concentrations that are achievable with all available dosage forms.Indocin® SR is a sustained release capsule of indomethacin designed to deliver 25 mg of drug immediately and 50 mg gradually. Absolute bioavailability of the product is 80%. The plasma concentration‐time curves do not show good sustained release characteristics; after four hours plasma concentrations resemble those seen with a single dose of regular capsules. The cost compared with Indocin® is competitive.Indos® is a zero‐order release form of indomethacin. It is a unique drug delivery system that shows good controlled release characteristics. Bioavailability is 85%.Both Indocin® SR and Indos® are apparently therapeutically equivalent to indomethacin capsules. In elderly patients, Indos® has been shown to be associated with fewer side effects than Indocin®. Both Indocin® SR and Indos® have the advantage of once or twice daily dosing.Keywords
This publication has 20 references indexed in Scilit:
- ‘Osmosin’ (sodium indomethacin trihydrate) in the treatment of elderly patients with osteoarthritisCurrent Medical Research and Opinion, 1983
- Biopharmaceutical evaluation of ‘Osmosin’Current Medical Research and Opinion, 1983
- Effect of sustained release on the pharmacokinetic profile of indomethacin in manBiopharmaceutics & Drug Disposition, 1982
- A DOUBLE-BLIND TRIAL COMPARING INDOMETHACIN SUSTAINED RELEASE CAPSULES (INDOCID-R) WITH INDOMETHACIN CAPSULES IN PATIENTS WITH RHEUMATOID ARTHRITISRheumatology, 1982
- Comparison of the in vitro dissolution behaviour of various indomethacin formulations with their in vivo bioavailabilityJournal of Pharmacy and Pharmacology, 1981
- Pharmacokinetics and Biochemical Effects in Responders and Non-Responders to Non-Steroidal Anti-Inflammatory DrugsScandinavian Journal of Rheumatology, 1981
- Indomethacin in rheumatoid arthritis: clinical effects, pharmacokinetics, and platelet studies in responders and nonrespondersAnnals of the Rheumatic Diseases, 1979
- Effects of concomitant aspirin administration on the pharmacokinetics of indomethacin in manJournal of Pharmacokinetics and Biopharmaceutics, 1978
- Indomethacin serum concentrations in man. Effects of dosage, food, and antacid.Annals of the Rheumatic Diseases, 1976
- Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid.Annals of the Rheumatic Diseases, 1973